Michael Friedlander

Michael Friedlander, MB ChB, PhD, FRACP is Professor of Medical Oncology at Prince of Wales Clinical School, University of New South Wales, and an attending medical oncologist at Prince of Wales Hospital in Sydney. He is one of Australia's most distinguished gynecologic oncologists and a globally influential figure in ovarian cancer clinical research, having served as former chair of the Australia New Zealand Gynaecological Oncology Group (ANZGOG) and co-chair of the Gynecologic Cancer InterGroup (GCIG). Professor Friedlander has been a principal investigator or key contributor to some of the most important ovarian cancer clinical trials of the past three decades, including the ICON series, SOLO-1 and SOLO-2, AGO-OVAR series, and multiple ANZGOG-led studies. He has made foundational contributions to understanding the clinical and biological behavior of BRCA1/2-mutant ovarian cancer — demonstrating superior chemosensitivity, distinct natural history, and exceptional responses to PARP inhibitor therapy in BRCA-mutant patients — contributing to the systematic integration of germline BRCA testing into ovarian cancer clinical practice. Professor Friedlander has led Australia's national framework for BRCA testing and genetic counseling in ovarian cancer patients and their families, and has contributed to GCIG consensus recommendations on clinical trial endpoint selection, response criteria, and quality-of-life measurement in ovarian cancer trials. He has authored over 250 peer-reviewed publications and is a founding contributor to patient advocacy and survivorship programs in gynecologic oncology in Australasia.